Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 144

Sort by

Sort Order Select

Journal Articles

Discovery of Novel IL3RA (CD123) Isoforms By Long Read Transcriptomics, Heterogeneous Expression Among AML Patient Cohorts and the Implications for Anti-CD123 Therapeutics

Jason G Underwood, PhD BA, Jenny L. Smith, MSc, MD, Lindsey F. Call, B.A., Elizabeth Tseng, PhD, Tiffany A. Hylkema, BS, Rhonda E. Ries, MA, Amanda R. Leonti, MS, Jason E. Farrar, MD, Timothy Junius Triche, Jr., PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 4658.

https://doi.org/10.1182/blood-2019-131508

Published: 2019

Journal Articles

Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells

Nadia El Khawanky, Bsc(Biomed), BHlthSc(Hons), Amy Hughes, PhD, Wenbo Yu, PhD, Sanaz Taromi, PhD, Jade Clarson, BSc, Angel F. Lopez, MD PhD, Michael P. Brown, MD PhD, Justus Duyster, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Deborah L. White, PhD FFSc (RCPA), Agnes S. M. Yong, MD PhD, Robert Zeiser, MD

Blood (2019) 134 (Supplement_1): 3904.

https://doi.org/10.1182/blood-2019-124684

Published: 2019

Journal Articles

Evaluation of a Bifunctional Sirpα-CD123 Fusion Antibody for the Elimination of Acute Myeloid Leukemia Stem Cells

Siret Tahk, Saskia Schmitt, Christian Peter Augsberger, Binje Vick, PhD, Laia Pascual Ponce, PhD, Irmela Jeremias, MD PhD, Georg Wittmann, MD, Nadja Fenn, PhD, Marion Subklewe, MD, Karl-Peter Hopfner, PhD

Blood (2019) 134 (Supplement_1): 2544.

https://doi.org/10.1182/blood-2019-128145

Published: 2019

Journal Articles

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Naval G. Daver, MD, Harry P. Erba, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, Daniel J. DeAngelo, MD, Eunice S. Wang, MD, Marina Y Konopleva, MD PhD, Callum M. Sloss, PhD, Jiuzhou Wang, PhD, Kara E. Malcolm, RN, Patrick A. Zweidler-McKay, MD PhD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 2601.

https://doi.org/10.1182/blood-2019-128501

Published: 2019

Journal Articles

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naval G. Daver, MD, Pau Montesinos, MD PhD, Daniel J. DeAngelo, MD, Eunice S. Wang, MD, Nikolaos Papadantonakis, MDPhDMSc, Eric Deconinck, MD PhD, Harry P. Erba, MD PhD, Naveen Pemmaraju, MD, Andrew A. Lane, MD PhD, David A. Rizzieri, MD, Kendra L. Sweet, MD, Giovanni Martinelli, Corrado Tarella, MD, Elisabetta Todisco, MD PhD, Marina Y Konopleva, MD PhD, Callum M. Sloss, PhD, Kerry Culm-Merdek, PhD, Patrick A. Zweidler-McKay, MD PhD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 734.

https://doi.org/10.1182/blood-2019-128648

Published: 2019

Journal Articles

Late-Stage Preclinical Characterization of Switchable CD123-Specific CAR-T for Treatment of Acute Leukemia

Simon Loff, MSc, Jan-Erik Meyer, Dipl. Biol., Josephine Dietrich, Msc, Johannes Spehr, PhD, Riewaldt Julia, PhD, Malte von Bonin, MD, Cordula Gründer, PhD, Kristin Franke, PhD, Anja Feldmann, PhD, Michael Bachmann, MD, Gerhard Ehninger, MD, Armin Ehninger, PhD, Marc Cartellieri, PhD

Blood (2018) 132 (Supplement 1): 964.

https://doi.org/10.1182/blood-2018-99-113288

Published: 2018

Journal Articles

Persistence of Exosomes in Patients with Acute Myeloid Leukemia in Complete Remission Suppresses Hematopoiesis

Swathi Namburi, MD, Hal E. Broxmeyer, PhD, Theresa L Whiteside, PhD, Michael Boyiadzis, MD

Blood (2018) 132 (Supplement 1): 3850.

https://doi.org/10.1182/blood-2018-99-115354

Published: 2018

Journal Articles

A Next-Generation Fc-Bearing CD3-Engaging Bispecific DART ® Platform with Extended Pharmacokinetic and Expanded Pharmacologic Window: Characterization As CD123 x CD3 and CD19 x CD3 DART Molecules

Ezio Bonvini, MD, Ross La Motte-Mohs, PhD, Ling Huang, Chia-Ying Kao Lam, PhD, Thomas Kaufman, Liqin Liu, PhD, Ralph F. Alderson, PhD, Kurt Stahl, Jennifer G. Brown, PhD, Hua Li, Sharad Sharma, PhD, James Tamura, PhD, Syd Johnson, PhD, Paul Moore, PhD

Blood (2018) 132 (Supplement 1): 5230.

https://doi.org/10.1182/blood-2018-99-116264

Published: 2018

Journal Articles

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart ® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2018) 132 (Supplement 1): 764.

https://doi.org/10.1182/blood-2018-99-117085

Published: 2018

Journal Articles

A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies

Naval G. Daver, MD, Harry P. Erba, MDPhD, Nikolaos Papadantonakis, MDPhDMSc, Daniel J. DeAngelo, MD, Eunice S. Wang, MD, Marina Y. Konopleva, MD PhD, Callum M. Sloss, PhD, Kerry Culm-Merdek, Patrick A. Zweidler-McKay, MD PhD, Hagop M. Kantarjian, MD

Blood (2018) 132 (Supplement 1): 27.

https://doi.org/10.1182/blood-2018-99-112955

Published: 2018

Journal Articles

Chromosome 21 Gain Is Dispensable for Transient Myeloproliferative Disorder (TMD) Development

Julius Lukes, Jr., MD, Eliska Potuckova, Julia Starkova, Jan Stary, MD PhD, Jan Zuna, Jan Trka, MD PhD, Marketa Zaliova

Blood (2018) 132 (Supplement 1): 2764.

https://doi.org/10.1182/blood-2018-99-112078

Published: 2018

Journal Articles

Critical Role of Jumonji Domain of JMJD1C in AML Leukemogenesis

Jesus Izaguirre-Carbonell, PhD, Christiansen Luke, Robert Burns, PhD, Jesse Schmitz, Chenxuan Li, Rebekah Mokry, Theresa Bluemn, Yongwei Zheng, Demin Wang, PhD, Nan Zhu, PhD

Blood (2018) 132 (Supplement 1): 2599.

https://doi.org/10.1182/blood-2018-99-110463

Published: 2018

Journal Articles

Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models

Claire Fritz, Scott M. Portwood, MS, MBA, Julie Adams, BS, Tara Cronin, BA, Linda Lutgen-Dunckley, Brandon L Martens, BS, Callum M. Sloss, PhD, Krystal Watkins, Yelena Kovtun, PhD, Sharlene Adams, PhD, Eunice S. Wang, MD

Blood (2018) 132 (Supplement 1): 2647.

https://doi.org/10.1182/blood-2018-99-117214

Published: 2018

Journal Articles

Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2017) 130 (Supplement 1): 1298.

https://doi.org/10.1182/blood.V130.Suppl_1.1298.1298

Published: 2017

Journal Articles

Plasma-Derived Exosomes Carrying Leukemia-Associated Antigens Associate with Leukemia Relapse in AML Patients after Chemotherapy

Michael Boyiadzis, MD, Chang Sook Hong, PhD, Theresa L Whiteside, PhD

Blood (2017) 130 (Supplement 1): 3921.

https://doi.org/10.1182/blood.V130.Suppl_1.3921.3921

Published: 2017

Journal Articles

Cord Blood NK Cells Engineered to Express a Humanized CD123-Targeted Chimeric Antigen Receptor (CAR) and IL-15 As Off-the-Shelf Therapy for Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 4453.

https://doi.org/10.1182/blood.V130.Suppl_1.4453.4453

Published: 2017

Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with Minimal Residual Disease (MRD)

Blood (2017) 130 (Supplement 1): 2583.

https://doi.org/10.1182/blood.V130.Suppl_1.2583.2583

Published: 2017

Journal Articles

CD123 Expression Patterns and Potential of IMGN632, a CD123-Targeted Antibody Drug Conjugate, in Acute Lymphoblastic Leukemia

Evgeniya Angelova, MD PhD, Charlene Audette, Yelena Kovtun, PhD, Naval Daver, MD, Sa A. Wang, MD, Sherry Pierce, BSN, BA, Sergej Naumovich Konoplev, MD PhD, Jeffrey L. Jorgensen, MD PhD, Marina Konopleva, MD PhD, Patrick A. Zweidler-McKay, MDPhD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Joseph David Khoury, MD

Blood (2017) 130 (Supplement 1): 2718.

https://doi.org/10.1182/blood.V130.Suppl_1.2718.2718

Published: 2017

Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis

Mrinal M. Patnaik, MDMBBS, Vikas Gupta, MD PhD, Gary J. Schiller, Sangmin Lee, MD, Abdulraheem Yacoub, MD, Haris Ali, MD, Moshe Talpaz, MD, Megan Sardone, Halyna Wysowskyj, Shay Shemesh, Janice Chen, PhD, Christopher Brooks, PhD, Trishna Goswami, MD, Animesh Pardanani, MBBS PhD, Ayalew Tefferi, MD, Srdan Verstovsek, MD PhD, Joseph David Khoury, MD, Naveen Pemmaraju, MD

Blood (2017) 130 (Supplement 1): 2908.

https://doi.org/10.1182/blood.V130.Suppl_1.2908.2908

Published: 2017

Journal Articles

Resistance to SL-401 in AML and BPDCN Is Associated with Loss of the Diphthamide Synthesis Pathway Enzyme DPH1 and Is Reversible By Azacitidine

Jason Stephansky, Katsuhiro Togami, MDPhD, Mahmoud Ghandi, PhD, Joan Montero, PhD, Nick vonEgypt, Ross Lindsay, PhD, Christopher Brooks, PhD, Jon C. Aster, MD PhD, Cory Johannessen, PhD, Andrew A. Lane, MD PhD

Blood (2017) 130 (Supplement 1): 797.

https://doi.org/10.1182/blood.V130.Suppl_1.797.797

Published: 2017

NARROW

Discovery of Novel IL3RA (CD123) Isoforms By Long Read Transcriptomics, Heterogeneous Expression Among AML Patient Cohorts and the Implications for Anti-CD123 Therapeutics

Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells

Evaluation of a Bifunctional Sirpα-CD123 Fusion Antibody for the Elimination of Acute Myeloid Leukemia Stem Cells

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Late-Stage Preclinical Characterization of Switchable CD123-Specific CAR-T for Treatment of Acute Leukemia

Persistence of Exosomes in Patients with Acute Myeloid Leukemia in Complete Remission Suppresses Hematopoiesis

A Next-Generation Fc-Bearing CD3-Engaging Bispecific DART ® Platform with Extended Pharmacokinetic and Expanded Pharmacologic Window: Characterization As CD123 x CD3 and CD19 x CD3 DART Molecules

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart ® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies

Chromosome 21 Gain Is Dispensable for Transient Myeloproliferative Disorder (TMD) Development

Critical Role of Jumonji Domain of JMJD1C in AML Leukemogenesis

Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models

Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Plasma-Derived Exosomes Carrying Leukemia-Associated Antigens Associate with Leukemia Relapse in AML Patients after Chemotherapy

Cord Blood NK Cells Engineered to Express a Humanized CD123-Targeted Chimeric Antigen Receptor (CAR) and IL-15 As Off-the-Shelf Therapy for Acute Myeloid Leukemia

Results from Ongoing Phase 1/2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with Minimal Residual Disease (MRD)

CD123 Expression Patterns and Potential of IMGN632, a CD123-Targeted Antibody Drug Conjugate, in Acute Lymphoblastic Leukemia

Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis

Resistance to SL-401 in AML and BPDCN Is Associated with Loss of the Diphthamide Synthesis Pathway Enzyme DPH1 and Is Reversible By Azacitidine

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only